IPHA
HEALTHCAREInnate Pharma
$1.51+0.11 (+7.86%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving IPHA Today?
No stock-specific AI insight has been generated for IPHA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.17$2.63
$1.51
Fundamentals
Market Cap$142M
P/E Ratio—
EPS$-0.64
Dividend Yield—
Dividend / Share—
ROE-2.7%
Profit Margin—
Debt / Equity—
Trading
Volume16K
Avg Volume (10D)—
Shares Outstanding93.8M
IPHA News
20 articles- Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business UpdateYahoo Finance·May 6, 2026
- Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsightGlobeNewswire Inc.·Apr 27, 2026
- Innate Pharma to Participate in the D. Boral Capital Global ConferenceYahoo Finance·Apr 23, 2026
- Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026Yahoo Finance·Apr 17, 2026
- Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026Yahoo Finance·Apr 13, 2026
- Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026Yahoo Finance·Apr 13, 2026
- Innate Pharma to Present at the AACR 2026 Oncology Industry Partnering EventYahoo Finance·Apr 8, 2026
- Innate Pharma to Participate in the Kempen Life Sciences ConferenceYahoo Finance·Apr 3, 2026
- Innate Pharma Files Its 2025 Universal Registration Document (Document D’enregistrement Universel) and 2025 Form 20-f Annual ReportYahoo Finance·Apr 2, 2026
- How Innate Pharma (ENXTPA:IPH) Story Is Shifting Around 2026 Catalysts And €8 TargetYahoo Finance·Mar 27, 2026
- Innate Pharma SA (IPHA) Full Year 2025 Earnings Call Highlights: Strategic Advances and ...Yahoo Finance·Mar 26, 2026
- Innate Pharma Q4 Earnings Call HighlightsMarketbeat·Mar 26, 2026
- Innate Pharma Reports Full Year 2025 Financial Results and Business UpdateYahoo Finance·Mar 26, 2026
- Innate Pharma Announces Conference Call and Webcast for Full Year 2025 Financial ResultsYahoo Finance·Mar 19, 2026
- Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026Yahoo Finance·Feb 19, 2026
- Innate Pharma to Participate in the Leerink Partners Global Healthcare ConferenceYahoo Finance·Feb 18, 2026
- Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025Yahoo Finance·Jan 7, 2026
- Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025Yahoo Finance·Dec 22, 2025
- Innate Pharma Releases Its 2026 Financial CalendarYahoo Finance·Dec 11, 2025
- Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025Yahoo Finance·Nov 28, 2025
All 20 articles loaded
Price Data
Open$1.48
Previous Close$1.40
Day High$1.56
Day Low$1.48
52 Week High$2.63
52 Week Low$1.17
52-Week Range
$1.17$2.63
$1.51
Fundamentals
Market Cap$142M
P/E Ratio—
EPS$-0.64
Dividend Yield—
Dividend / Share—
ROE-2.7%
Profit Margin—
Debt / Equity—
Trading
Volume16K
Avg Volume (10D)—
Shares Outstanding93.8M
About Innate Pharma
Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France and internationally. The company is headquartered in Marseille, France.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—